A FAMILY WITH HIGH SERUM LEUCINE AMINOPEPTIDASE ACTIVITY DERIVED FROMA NOVEL VARIANT CD13
Citation
M. Kawai et al., A FAMILY WITH HIGH SERUM LEUCINE AMINOPEPTIDASE ACTIVITY DERIVED FROMA NOVEL VARIANT CD13, Clinical chemistry, 44(2), 1998, pp. 215-220
Categorie Soggetti
Medical Laboratory Technology
SICI code
0009-9147(1998)44:2<215:AFWHSL>2.0.ZU;2-6
Abstract
We investigated a family in which some individuals showed extremely hi
gh serum leucine aminopeptidase (LAP) (EC 3.4.11.2) activity, mainly d
erived from a variant CD13. The isoelectric points of the variant and
normal CD13 were 3.3 and 4.1, respectively, and both points converged
at 4.4 after treatment with neuraminidase, indicating that more sialic
acids are bound to the variant CD13 than normal. The molecular masses
of both CD13s were 144 kDa by sodium dodecyl sulfate-polyacrylamide g
el electrophoresis. After treatment with neuraminidase, N-glycosidase,
and O-glycosidase, apparent molecular masses of the variant and norma
l CD13 were 106 kDa and 100 kDa, respectively, suggesting that the var
iant CD13 contains a longer peptide than normal. This is the first cas
e of familial high serum LAP activity in which the origin could be dem
onstrated by anti-CD13 monoclonal antibodies to be a variant CD13 inhe
rited in an autosomal dominant mode. The isoelectric point of the LAP
activity after neuraminidase treatment was different from that previou
sly reported.